CDK8-IN-6

• Description :

  CDK8-IN-6 (compound 9) is a potent cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 13 nM. CDK8-IN-6 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 11.2, 7.5, 8.6, 20.5, 12.5-25 µM, respectively. CDK8-IN-6 has the potential for the research of AML-cancer[1].

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cdk8-in-6.html

• Solubility :

  10 mM in DMSO

• Smiles :

  C[C@@]12C(C3=CC(Cl)=CN=C3)=CC[C@@]1([H])[C@]4([H])CC[C@@]5([H])C[C@H](N(C)C)CC[C@]5(C)[C@@]4([H])CC2

• Molecular Formula :

  C26H37ClN2

• Molecular Weight :

  413.04

• References & Citations :

  [1]Solum E, et al. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation. Bioorg Med Chem. 2020 May 15;28 (10) :115461.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK8

• CAS Number :

  [2415156-27-1]